Investigation Launched into Fairness of Paragon 28, Inc. Buyout
PHILADELPHIA, PA – March 25, 2025
Kaskela Law LLC, a securities law firm based in Philadelphia, has announced that it is investigating the proposed buyout of Paragon 28, Inc. (Paragon) (NYSE: FNA) and its potential impact on shareholders. The firm is examining whether the proposed transaction undervalues the company and whether Paragon’s board of directors breached their fiduciary duties in agreeing to the deal.
Background of the Proposed Buyout
On March 1, 2025, Paragon announced that it had entered into a definitive agreement to be acquired by a leading global medical device company for approximately $1.2 billion. Under the terms of the agreement, Paragon shareholders will receive $32.50 in cash for each share of Paragon common stock they own.
Investigation Details
Kaskela Law LLC is investigating the fairness of the proposed buyout price to Paragon shareholders. The firm is examining the valuation of Paragon and the process by which the company’s board of directors considered and approved the transaction. Specifically, the investigation will focus on:
- The adequacy of the process and deliberation by Paragon’s board of directors in considering the proposed buyout;
- Whether Paragon’s board of directors acted in the best interests of the company and its shareholders in agreeing to the transaction;
- Whether the proposed buyout price undervalues Paragon’s stock;
Impact on Shareholders
If you are a Paragon shareholder and believe that the proposed buyout price undervalues your shares, or if you have concerns about the process by which the buyout was approved, you may be eligible to join the investigation. Kaskela Law LLC encourages Paragon shareholders to contact the firm for a free, no-obligation consultation to discuss their legal rights and options.
Impact on the World
The investigation into the fairness of the Paragon buyout could have significant implications for the medical device industry and corporate governance as a whole. If it is determined that Paragon’s board of directors breached their fiduciary duties or undervalued the company, it could lead to increased scrutiny of similar transactions in the future. Additionally, it could result in increased pressure on companies to provide more transparency and disclosure around their merger and acquisition processes.
Conclusion
In conclusion, the investigation into the fairness of the Paragon 28 buyout is an important development for shareholders and the medical device industry. Kaskela Law LLC is committed to ensuring that Paragon’s shareholders receive full and fair compensation for their shares. If you are a Paragon shareholder and have concerns about the proposed buyout, contact Kaskela Law LLC to discuss your legal rights and options.
Stay informed about the latest developments in the Paragon buyout investigation by following Kaskela Law LLC on Twitter @kaskelalawllc or visiting their website at
